Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Reusch

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Mabs|June 8, 2019
Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunityKristina Ellwanger, Uwe Reusch, Ivica Fucek, et al.
Mabs|March 28, 2014
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cellsUwe Reusch, Carmen Burkhardt, Ivica Fucek, et al.
Scientific Reports|September 20, 2013
Anti-LRP/LR specific antibody IgG1-iS18 and knock-down of LRP/LR by shRNAs rescue cells from Aβ42 induced cytotoxicityBianca Da Costa Dias, Katarina Jovanovic, Danielle Gonsalves, et al.
Protein Engineering, Design & Selection : PEDS|October 6, 2017
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cellsThorsten Gantke, Michael Weichel, Carmen Herbrecht, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 6, 2013
Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patientsKatrin S Reiners, Jörg Kessler, Maike Sauer, et al.
Molecular Immunology|June 20, 2007
Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseasesChantal Zuber, Stefan Knackmuss, Clémence Rey, et al.
The Journal of General Virology|July 18, 2008
Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapyChantal Zuber, Gerda Mitteregger, Natascha Schuhmann, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2019
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11Johannes Duell, Dragana S Lukic, Margarete Karg, et al.
Journal of Alzheimer'S Disease : JAD|October 21, 2015
LRP/LR Antibody Mediated Rescuing of Amyloid-β-Induced Cytotoxicity is Dependent on PrPc in Alzheimer's DiseaseEmma C Pinnock, Katarina Jovanovic, Maxine G Pinto, et al.
Plos One|November 7, 2015
Knock-Down of the 37kDa/67kDa Laminin Receptor LRP/LR Impedes Telomerase ActivityKerrilyn Naidoo, Sibusiso T Malindisa, Tyrone C Otgaar, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Mabs|June 8, 2019
Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunityKristina Ellwanger, Uwe Reusch, Ivica Fucek, et al.
Mabs|March 28, 2014
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cellsUwe Reusch, Carmen Burkhardt, Ivica Fucek, et al.
Scientific Reports|September 20, 2013
Anti-LRP/LR specific antibody IgG1-iS18 and knock-down of LRP/LR by shRNAs rescue cells from Aβ42 induced cytotoxicityBianca Da Costa Dias, Katarina Jovanovic, Danielle Gonsalves, et al.
Protein Engineering, Design & Selection : PEDS|October 6, 2017
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cellsThorsten Gantke, Michael Weichel, Carmen Herbrecht, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 6, 2013
Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patientsKatrin S Reiners, Jörg Kessler, Maike Sauer, et al.
Molecular Immunology|June 20, 2007
Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseasesChantal Zuber, Stefan Knackmuss, Clémence Rey, et al.
The Journal of General Virology|July 18, 2008
Delivery of single-chain antibodies (scFvs) directed against the 37/67 kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapyChantal Zuber, Gerda Mitteregger, Natascha Schuhmann, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2019
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11Johannes Duell, Dragana S Lukic, Margarete Karg, et al.
Journal of Alzheimer'S Disease : JAD|October 21, 2015
LRP/LR Antibody Mediated Rescuing of Amyloid-β-Induced Cytotoxicity is Dependent on PrPc in Alzheimer's DiseaseEmma C Pinnock, Katarina Jovanovic, Maxine G Pinto, et al.
Plos One|November 7, 2015
Knock-Down of the 37kDa/67kDa Laminin Receptor LRP/LR Impedes Telomerase ActivityKerrilyn Naidoo, Sibusiso T Malindisa, Tyrone C Otgaar, et al.
Pageof 4